Please contact us for more information or to learn if you are eligible to participate.
The primary objectives are to evaluate the efficacy, safety, and tolerability of aldafermin based on liver histology at 24 weeks versus placebo
Principal Investigator | Jose Luis Almeda, MD |
Co-PI | Guillermo Duran |
Sponsor | NGM Biopharmaceuticals, Inc. |
Type of Trial | Interventional |